E Genton, J Hirsh. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Anticoagulants/therapeutic useFibrinolytic Agents/adverse effectsFibrinolytic Agents/therapeutic useHeparin/administration & dosageHeparin/adverse effectsHeparin/therapeutic useHumansInfusions, Parenteral/methodsInjections, SubcutaneousPulmonary Embolism/drug therapyStreptokinase/therapeutic useTime FactorsUrokinase-Type Plasminogen Activator/therapeutic use
Substances: See more » AnticoagulantsFibrinolytic AgentsHeparinStreptokinaseUrokinase-Type Plasminogen Activator
Year: 1975 PMID: 1129499 DOI: 10.1016/s0033-0620(75)80010-7
Source DB: PubMed Journal: Prog Cardiovasc Dis ISSN: 0033-0620 Impact factor: 8.194